Relative efficacy and safety of ticagelor vs clopidogrel as a
function of time to invasive management in non-ST-segment
elevation acute coronary syndrome in the PLATO trial

J 2017

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial

POLLACK, C.V., F. DAVOUDI, D.B. DIERCKS, R.C. BECKER, S.K. JAMES et. al.

Základní údaje

Originální název

Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial

Autoři

POLLACK, C.V. (840 Spojené státy), F. DAVOUDI (840 Spojené státy), D.B. DIERCKS (840 Spojené státy), R.C. BECKER (840 Spojené státy), S.K. JAMES (752 Švédsko), S.T. LIM (702 Singapur), P.J. SCHULTE (840 Spojené státy), Jindřich ŠPINAR (203 Česká republika, garant, domácí), P.G. STEG (250 Francie), R.F. STOREY (840 Spojené státy), A. HIMMELMANN (752 Švédsko), L. WALLENTIN (752 Švédsko) a C.P. CANNON (840 Spojené státy)

Vydání

Clinical Cardiology, Hoboken, John Wiley and Sons Inc. 2017, 0160-9289

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 2.733

Kód RIV

RIV/00216224:14110/17:00097701

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1002/clc.22733

UT WoS

000405393200007

Klíčová slova anglicky

Non-ST-Segment Elevation Acute Coronary Syndromes (NSTE-ACS); Antiplatelet Therapy; P2Y(12) Receptor Antagonists; Clopidogrel; Ticagrelor; Angiography

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 3. 2018 19:00, Soňa Böhmová

Anotace

V originále

Background: Guidelines suggest that "upstream" P2Y(12) receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). Hypothesis: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. Methods: In the PLATO trial, 6792 NSTE-ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (>= 3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. Results: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs >= 3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, P-int = 0.002). Patterns were similar at 30 days and 1 year. Conclusions: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor

Citovat

POLLACK, C.V., F. DAVOUDI, D.B. DIERCKS, R.C. BECKER, S.K. JAMES, S.T. LIM, P.J. SCHULTE, Jindřich ŠPINAR, P.G. STEG, R.F. STOREY, A. HIMMELMANN, L. WALLENTIN a C.P. CANNON. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. Clinical Cardiology. Hoboken: John Wiley and Sons Inc., 2017, roč. 40, č. 6, s. 390-398. ISSN 0160-9289. Dostupné z: https://dx.doi.org/10.1002/clc.22733.

@article{1390859,
   author = {Pollack, C.V. and Davoudi, F. and Diercks, D.B. and Becker, R.C. and James, S.K. and Lim, S.T. and Schulte, P.J. and Špinar, Jindřich and Steg, P.G. and Storey, R.F. and Himmelmann, A. and Wallentin, L. and Cannon, C.P.},
   article_location = {Hoboken},
   article_number = {6},
   doi = {http://dx.doi.org/10.1002/clc.22733},
   keywords = {Non-ST-Segment Elevation Acute Coronary Syndromes (NSTE-ACS); Antiplatelet Therapy; P2Y(12) Receptor Antagonists; Clopidogrel; Ticagrelor; Angiography},
   language = {eng},
   issn = {0160-9289},
   journal = {Clinical Cardiology},
   title = {Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial},
   volume = {40},
   year = {2017}
}

TY  - JOUR
ID  - 1390859
AU  - Pollack, C.V. - Davoudi, F. - Diercks, D.B. - Becker, R.C. - James, S.K. - Lim, S.T. - Schulte, P.J. - Špinar, Jindřich - Steg, P.G. - Storey, R.F. - Himmelmann, A. - Wallentin, L. - Cannon, C.P.
PY  - 2017
TI  - Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial
JF  - Clinical Cardiology
VL  - 40
IS  - 6
SP  - 390-398
EP  - 390-398
PB  - John Wiley and Sons Inc.
SN  - 01609289
KW  - Non-ST-Segment Elevation Acute Coronary Syndromes (NSTE-ACS)
KW  - Antiplatelet Therapy
KW  - P2Y(12) Receptor Antagonists
KW  - Clopidogrel
KW  - Ticagrelor
KW  - Angiography
N2  - Background: Guidelines suggest that "upstream" P2Y(12) receptor antagonists should be considered in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS). Hypothesis: Early use of ticagrelor in patients managed with an invasive strategy would be more effective than clopidogrel because of its more rapid onset of action and greater potency. Methods: In the PLATO trial, 6792 NSTE-ACS patients were randomized to ticagrelor or clopidogrel (started prior to angiography) and underwent angiography within 72 hours of randomization. We compared efficacy and safety outcomes of ticagrelor vs clopidogrel as a function of "early" (<3h) vs "late" (>= 3h) time to angiography. Adjusted Cox proportional hazards models evaluated interaction between randomized treatment and time from randomization to angiography on subsequent outcomes. Results: Overall, a benefit of ticagrelor vs clopidogrel for cardiovascular death/myocardial infarction/stroke was seen at day 7 (hazard ratio [HR]: 0.67, P = 0.002), day 30 (HR: 0.81, P = 0.042), and 1 year (HR: 0.80, P = 0.0045). There were no significant interactions in the <3h vs >= 3h groups at any timepoint. For major bleeding, overall there was no significant increase (HR: 1.04, 95% confidence interval: 0.85-1.27); but there was a significant interaction with no difference between ticagrelor and clopidogrel in the early group (HR: 0.79), but higher bleeding risk with ticagrelor in the late angiography group, at 7 days (HR: 1.51, P-int = 0.002). Patterns were similar at 30 days and 1 year. Conclusions: The benefit of ticagrelor over clopidogrel was consistent in those undergoing early and late angiography, supporting upstream use of ticagrelor
ER  -

POLLACK, C.V., F. DAVOUDI, D.B. DIERCKS, R.C. BECKER, S.K. JAMES, S.T. LIM, P.J. SCHULTE, Jindřich ŠPINAR, P.G. STEG, R.F. STOREY, A. HIMMELMANN, L. WALLENTIN a C.P. CANNON. Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial. \textit{Clinical Cardiology}. Hoboken: John Wiley and Sons Inc., 2017, roč.~40, č.~6, s.~390-398. ISSN~0160-9289. Dostupné z: https://dx.doi.org/10.1002/clc.22733.

Podrobný výpis o publikaci